|
|
Article: Boston Biomedica Announces the Availability of a New Test for Lyme Disease.
- Article from:
- PR Newswire
- Article date:
- August 28, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BBI Clinical Laboratories Will Be First To Offer The 3rd Generation Test
WEST BRIDGEWATER, Mass., Aug. 28 /PRNewswire/ --
Boston Biomedica, Inc. (Nasdaq: BBII) announced today that BBI Clinical Laboratories of New Britain, CT (a wholly-owned subsidiary of Boston Biomedica) has launched a new antibody test for Lyme Disease called the C6 Lyme Peptide ELISA (VlsE). There is a nationwide market for Lyme Disease testing, but accurate diagnosis has been hampered to date by inadequate tests. The Company believes that this new test offers a significant breakthrough in accuracy. BBI Clinical Laboratories is the first reference laboratory to make this test ...